Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 141
Filter
1.
IJTLD Open ; 1(2): 83-89, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38966690

ABSTRACT

BACKGROUND: Both 1 month of daily (1HP) and 3 months of weekly (3HP) isoniazid-rifapentine are recommended as short-course regimens for TB prevention among people living with HIV (PLHIV). We aimed to assess acceptability and preferences for 1HP vs. 3HP among PLHIV. METHODS: In a cross-sectional survey among PLHIV at an HIV clinic in Kampala, Uganda, participants were randomly assigned to a hypothetical scenario of receiving 1HP or 3HP. Participants rated their level of perceived intention and confidence to complete treatment using a 0-10 Likert scale, and chose between 1HP and 3HP. RESULTS: Among 429 respondents (median age: 43 years, 71% female, median time on ART: 10 years), intention and confidence were rated high for both regimens. Intention to complete treatment was rated at least 7/10 by 92% (189/206 randomized to 1HP) and 93% (207/223 randomized to 3HP). Respectively 86% (178/206) and 93% (208/223) expressed high confidence to complete treatment. Overall, 81% (348/429) preferred 3HP over 1HP. CONCLUSIONS: Both 1HP and 3HP were highly acceptable regimens, with 3HP preferred by most PLHIV. Weekly, rather than daily, dosing appears preferable to shorter duration of treatment, which should inform scale-up and further development of short-course regimens for TB prevention.


CONTEXTE: L'association isoniazide-rifapentine est recommandée comme traitement de courte durée pour la prévention de la TB chez les personnes vivant avec le VIH (PVVIH), à raison d'un mois de traitement quotidien (1HP) et de 3 mois de traitement hebdomadaire (3HP). Nous avons cherché à évaluer l'acceptabilité et les préférences des PVVIH pour le traitement 1HP par rapport au traitement 3HP. MÉTHODES: Dans le cadre d'une enquête transversale menée auprès de PVVIH dans une clinique VIH de Kampala, en Ouganda, les participants ont été assignés de manière aléatoire à un scénario hypothétique de réception de 1HP ou de 3HP. Les participants ont évalué leur niveau d'intention perçue et de confiance pour terminer le traitement en utilisant une échelle de Likert de 0 à 10 et ont choisi entre 1HP et 3HP. RÉSULTATS: Parmi les 429 répondants (âge médian : 43 ans, 71% de femmes, durée médiane de la thérapie antirétrovirale : 10 ans), l'intention et la confiance ont été jugées élevées pour les deux schémas. L'intention de terminer le traitement a été évaluée à au moins 7/10 par 92% (189/206 randomisés pour 1HP) et 93% (207/223 randomisés pour 3HP). Respectivement 86% (178/206) et 93% (208/223) ont exprimé une grande confiance dans le fait de terminer le traitement. Dans l'ensemble, 81% (348/429) ont préféré la 3HP à la 1HP. CONCLUSION: Les schémas 1HP et 3HP étaient tous deux très acceptables, le schéma 3HP étant préféré par la plupart des PVVIH. L'administration hebdomadaire, plutôt que quotidienne, semble préférable à une durée de traitement plus courte, ce qui devrait inspirer l'extension et le développement de schémas thérapeutiques de courte durée pour la prévention de la TB.

2.
Int J Tuberc Lung Dis ; 27(6): 458-464, 2023 06 01.
Article in English | MEDLINE | ID: mdl-37231600

ABSTRACT

BACKGROUND: Twelve weeks of weekly isoniazid and rifapentine (3HP) prevents TB disease among people with HIV (PWH), but the costs to people of taking TB preventive treatment is not well described.METHODS: We surveyed PWH who initiated 3HP at a large urban HIV/AIDS clinic in Kampala, Uganda, as part of a larger trial. We estimated the cost of one 3HP visit from the patient perspective, including both out-of-pocket costs and estimated lost wages. Costs were reported in 2021 Ugandan shillings (UGX) and US dollars (USD; USD1 = UGX3,587)RESULTS: The survey included 1,655 PWH. The median participant cost of one clinic visit was UGX19,200 (USD5.36), or 38.5% of the median weekly income. Per visit, the cost of transportation was the largest component (median: UGX10,000/USD2.79), followed by lost income (median: UGX4,200/USD1.16) and food (median: UGX2,000/USD0.56). Men reported greater income loss than women (median: UGX6,400/USD1.79 vs. UGX3,300/USD0.93), and participants who lived further than a 30-minute drive to the clinic had higher transportation costs than others (median: UGX14,000/USD3.90 vs. UGX8,000/USD2.23).CONCLUSION: Patient-level costs to receive 3HP accounted for over one-third of weekly income. Patient-centered approaches to averting or defraying these costs are needed.


Subject(s)
Acquired Immunodeficiency Syndrome , Latent Tuberculosis , Tuberculosis , Male , Humans , Female , Isoniazid/therapeutic use , Antitubercular Agents/therapeutic use , Uganda , Tuberculosis/drug therapy , Latent Tuberculosis/drug therapy , Drug Therapy, Combination , Acquired Immunodeficiency Syndrome/drug therapy
5.
Bone Marrow Transplant ; 48(2): 257-64, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22750998

ABSTRACT

High incidences of human herpesvirus (HHV)-6 encephalitis have recently been reported from several Japanese SCT centers. To evaluate the effect of low-dose foscarnet (PFA) in preventing HHV-6 infection among recipients of unrelated BM or cord blood (CB), we examined consecutive cohorts without prophylaxis against HHV-6 (cohort 1, n=51) and with PFA prophylaxis (cohort 2, PFA 50 mg/kg/day for 10 days after engraftment, n=67). Plasma real-time PCR assay was performed weekly. High-level reactivation defined as HHV-6 DNA > or =10(4) copies/mL by day 70 was the primary endpoint. No significant reduction of high-level reactivation was seen in cohort 2 (19.4%) compared with cohort 1 (33.8%, P=0.095). A trend was identified toward fewer high-level HHV-6 reactivations in cohort 2 among recipients of unrelated BM (P=0.067), but no difference in incidence was observed among CB recipients (P=0.75). Breakthrough HHV-6 encephalitis occurred following PFA prophylaxis in three patients, and incidence of HHV-6 encephalitis did not differ between cohort 1 (9.9%) and cohort 2 (4.5%, P=0.24). In conclusion, 50 mg/kg/day of PFA does not effectively suppress HHV-6 reactivation and cannot prevent all cases of HHV-6 encephalitis. To effectively prevent HHV-6 encephalitis, alternative approaches based on the pathogenesis of HHV-6 encephalitis will probably be required.


Subject(s)
Antiviral Agents/therapeutic use , Encephalitis, Viral/drug therapy , Foscarnet/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/methods , Herpesvirus 6, Human/physiology , Roseolovirus Infections/drug therapy , Adolescent , Adult , Aged , Cohort Studies , Encephalitis, Viral/etiology , Encephalitis, Viral/prevention & control , Encephalitis, Viral/virology , Humans , Incidence , Middle Aged , Roseolovirus Infections/etiology , Roseolovirus Infections/prevention & control , Roseolovirus Infections/virology , Transplantation, Homologous , Virus Activation/drug effects , Young Adult
6.
Br J Radiol ; 85(1020): 1533-8, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22844034

ABSTRACT

OBJECTIVE: The aim of this study was to assess clinical and pulmonary thin-section CT findings in patients with acute Pseudomonas aeruginosa (PA) pulmonary infection. METHODS: We retrospectively identified 44 patients with acute PA pneumonia who had undergone chest thin-section CT examinations between January 2004 and December 2010. We excluded nine patients with concurrent infections. The final study group comprised 35 patients (21 males, 14 females; age range 30-89 years, mean age 66.9 years) with PA pneumonia. The patients' clinical findings were assessed. Parenchymal abnormalities, enlarged lymph nodes and pleural effusion were evaluated on thin-section CT. RESULTS: Underlying diseases included malignancy (n=13), a smoking habit (n=11) and cardiac disease (n=8). CT scans of all patients revealed abnormal findings, including ground-glass opacity (n=34), bronchial wall thickening (n=31), consolidation (n=23) and cavities (n=5). Pleural effusion was found in 15 patients. CONCLUSION: PA pulmonary infection was observed in patients with underlying diseases such as malignancy or a smoking habit. The CT findings in patients with PA consisted mainly of ground-glass attenuation and bronchial wall thickening. ADVANCES IN KNOWLEDGE: The CT findings consisted mainly of ground-glass attenuation, bronchial wall thickening and cavities. These findings in patients with an underlying disease such as malignancy or a smoking habit may be suggestive of pneumonia caused by PA infection.


Subject(s)
Pneumonia, Bacterial/diagnostic imaging , Pseudomonas Infections/diagnostic imaging , Pseudomonas aeruginosa , Tomography, X-Ray Computed/methods , Acute Disease , Adult , Aged , Aged, 80 and over , Community-Acquired Infections/diagnostic imaging , Cross Infection/diagnostic imaging , Female , Humans , Male , Middle Aged , Retrospective Studies
7.
Clin Exp Immunol ; 168(2): 234-40, 2012 May.
Article in English | MEDLINE | ID: mdl-22471285

ABSTRACT

Statins are 3-hydroxy-3-methylglutaryl-co-enzyme A reductase inhibitors of cholesterol biosynthesis, and have been reported to exert pleiotropic effects on cellular signalling and cellular functions involved in inflammation. Recent reports have demonstrated that previous statin therapy reduced the risk of pneumonia or increased survival in patients with community-acquired pneumonia. However, the precise mechanisms responsible for these effects are unclear. In the present study, we examined the effects of statins on cytokine production from lipopolysaccharide (LPS)-stimulated human bronchial epithelial cells (BEAS-2B). Interleukin (IL)-6 and IL-8 mRNA expression and protein secretion in LPS-stimulated cells were inhibited significantly by the lipophilic statin pitavastatin and the hydrophilic statin pravastatin. As these inhibitory effects of statin were negated by adding mevalonate, the anti-inflammatory effects of statins appear to be exerted via the mevalonic cascade. In addition, the activation levels of Ras homologue gene family A (RhoA) in BEAS-2B cells cultured with pitavastatin were significantly lower than those without the statin. These results suggest that statins have anti-inflammatory effects by reducing cytokine production through inhibition of the mevalonic cascade followed by RhoA activation in the lung.


Subject(s)
Cytokines/biosynthesis , Epithelial Cells/drug effects , Epithelial Cells/immunology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Inflammation Mediators/metabolism , Respiratory Mucosa/drug effects , Respiratory Mucosa/immunology , Bronchi/cytology , Cell Line , Enzyme Activation/drug effects , Humans , Mevalonic Acid/pharmacology , Pravastatin/pharmacology , rhoA GTP-Binding Protein/metabolism
8.
QJM ; 104(2): 133-9, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20870780

ABSTRACT

BACKGROUND: Although it is well known that aspirin causes gastroduodenal mucosal injury and that aspirin-induced gastroduodenal mucosal injury is often asymptomatic, the prevalence and independent factors for gastroduodenal mucosal injury have not been clarified in asymptomatic patients taking low-dose aspirin and gastroprotective agents. AIM: To clarify the prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents. DESIGN: Prospective observational study. METHODS: We performed endoscopy in 150 asymptomatic patients taking low-dose aspirin and gastroprotective agents for at least 3 months. RESULTS: Gastroduodenal ulcers/erosions were observed in 37.3% [ulcers (4.0%); erosions (34.0%)]. Univariate logistic regression analyses showed that proton-pump inhibitor (PPI) use was negatively associated with gastroduodenal ulcers/erosions [odds ratio (OR) 0.35, 95% confidence interval (95% CI) 0.17-0.75, P=0.007]. A multivariate logistic regression analysis selected PPI use as the only independent factor for gastroduodenal ulcers/erosions (OR 0.35, 95% CI 0.14-0.86, P=0.02). None of the 53 patients with PPI use had any gastroduodenal ulcers, and 11 with standard-dose PPI use tended to have a lower prevalence of gastroduodenal erosions than 42 with low-dose PPI use (0% vs. 28.6%, P=0.052). CONCLUSION: Gastroduodenal ulcers/erosions were observed in about one-third of asymptomatic patients taking low-dose aspirin and gastroprotective agents, and PPI use was a negative independent factor for gastroduodenal ulcers/erosions in those patients. In addition, standard-dose PPI therapy might be more effective in the prevention of aspirin-induced gastroduodenal mucosal injury than low-dose PPI therapy.


Subject(s)
Aspirin/adverse effects , Peptic Ulcer/chemically induced , Platelet Aggregation Inhibitors/adverse effects , Proton Pump Inhibitors/therapeutic use , Aged , Aged, 80 and over , Aspirin/administration & dosage , Drug Administration Schedule , Endoscopy, Gastrointestinal , Epidemiologic Methods , Female , Humans , Male , Middle Aged , Peptic Ulcer/epidemiology , Peptic Ulcer/prevention & control , Platelet Aggregation Inhibitors/administration & dosage
9.
Br J Radiol ; 84(997): e4-6, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21172960

ABSTRACT

Giant cell carcinoma of the lung is a very rare primary malignant tumour and localised right upper-lobe pulmonary oedema is also unusual. We report a case of giant cell carcinoma, which invaded the left atrium through the left pulmonary vein and caused localised right upper-lobe pulmonary oedema.


Subject(s)
Carcinoma, Giant Cell/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Mitral Valve/diagnostic imaging , Pulmonary Edema/diagnostic imaging , Carcinoma, Giant Cell/pathology , Cough/etiology , Fatal Outcome , Hemoptysis/etiology , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Mitral Valve/pathology , Neoplasm Invasiveness , Pulmonary Edema/etiology , Pulmonary Veins/diagnostic imaging , Pulmonary Veins/pathology , Radiography
10.
Br J Radiol ; 84(999): 229-35, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21045068

ABSTRACT

OBJECTIVE: This study aimed to compare thin-section CT images from sarcoidosis patients who had either normal or elevated serum KL-6 levels. METHODS: 101 patients with sarcoidosis who underwent thin-section CT examinations of the chest and serum KL-6 measurements between December 2003 and November 2008 were retrospectively identified. The study group comprised 75 sarcoidosis patients (23 male, 52 female; aged 19-82 years, mean 54.1 years) with normal KL-6 levels (152-499 U ml(-1), mean 305.7 U ml(-1)) and 26 sarcoidosis patients (7 male, 19 female; aged 19-75 years, mean 54.3 years) with elevated KL-6 levels (541-2940 U ml(-1), mean 802.4 U ml(-1)). Two chest radiologists, unaware of KL-6 levels, retrospectively and independently interpreted CT images for parenchymal abnormalities, enlarged lymph nodes and pleural effusion. RESULTS: CT findings in sarcoidosis patients consisted mainly of lymph node enlargement (70/75 with normal KL-6 levels and 21/26 with elevated KL-6 levels), followed by nodules (50 and 25 with normal and elevated levels, respectively) and bronchial wall thickening (25 and 21 with normal and elevated levels, respectively). Ground-glass opacity, nodules, interlobular septal thickening, traction bronchiectasis, architectural distortion and bronchial wall thickening were significantly more frequent in patients with elevated KL-6 levels than those with normal levels (p<0.001, p<0.005, p<0.001, p<0.001, p<0.001 and p<0.001, respectively). By comparison, there was no significant difference in frequency of lymph node enlargement between the two groups. CONCLUSION: These results suggest that serum KL-6 levels may be a useful marker for indicating the severity of parenchymal sarcoidosis.


Subject(s)
Lung/diagnostic imaging , Lymph Nodes/diagnostic imaging , Mucin-1/blood , Sarcoidosis, Pulmonary/diagnostic imaging , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Bronchoalveolar Lavage Fluid , Female , Humans , Lung/pathology , Lymph Nodes/pathology , Male , Microtomy , Middle Aged , Retrospective Studies , Sarcoidosis, Pulmonary/blood , Sarcoidosis, Pulmonary/pathology , Tomography, X-Ray Computed/methods , Young Adult
11.
Br J Radiol ; 83(996): e255-8, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21088083

ABSTRACT

Human herpesvirus 6 (HHV-6)-associated encephalitis or pneumonitis has been reported in immunocompetent and immunosuppressed individuals. Several MRI studies in patients with HHV-6-associated encephalitis have been presented. However, to the best of our knowledge, no studies describing thin-section CT imaging in patients with HHV-6-associated pneumonitis have been reported. Here we describe a case of HHV-6-associated encephalitis and pneumonitis that developed after bone marrow transplantation. Thin-section CT images of the chest revealed ground-glass attenuation, consolidation and centrilobular nodules in both lungs.


Subject(s)
Bone Marrow Transplantation/adverse effects , Encephalitis, Viral/virology , Herpesviridae Infections/virology , Herpesvirus 6, Human , Pneumonia, Viral/virology , DNA, Viral/isolation & purification , Herpesvirus 6, Human/genetics , Herpesvirus 6, Human/isolation & purification , Humans , Immunocompromised Host , Male , Middle Aged
12.
Bone Marrow Transplant ; 45(1): 129-36, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19465942

ABSTRACT

This study investigated factors associated with the development of human herpesvirus (HHV)-6 encephalitis. Among 111 enrolled subjects, 12 patients developed central nervous system (CNS) dysfunction. CNS dysfunction in four patients was found to have no association with HHV-6. The remaining eight patients displayed HHV-6 encephalitis (n=3), limbic encephalitis (HHV-6 DNA in cerebrospinal fluid was not examined; n=3) or CNS dysfunction because of an unidentified cause (n=2). Real-time PCR showed CNS dysfunction in the latter eight patients, which developed concomitant with the appearance of high plasma levels of HHV-6 DNA (> or =10(4) copies/ml). Overall, eight of the 24 patients with high-level HHV-6 DNA developed CNS dysfunction, whereas no patients developed CNS dysfunction potentially associated with HHV-6 infection if peak HHV-6 DNA was <10(4) copies/ml. We next analyzed plasma concentrations of IL-6, IL-10 and tumor necrosis factor-alpha among patients who displayed high-level plasma HHV-6 DNA and found elevated IL-6 concentrations preceding HHV-6 infection in patients who developed CNS dysfunction. (Mean+/-s.d.: 865.7+/-1036.3 pg/ml in patients with CNS dysfunction; 56.5+/-192.9 pg/ml in others; P=0.01). These results suggest that high-level HHV-6 load is necessary for the development of HHV-6 encephalitis, and systemic inflammatory conditions before HHV-6 infection form the preparatory conditions for progression to encephalopathy.


Subject(s)
Encephalitis, Viral/virology , Herpesvirus 6, Human , Interleukin-6/blood , Roseolovirus Infections/virology , Stem Cell Transplantation/adverse effects , Adolescent , Adult , Child , DNA, Viral/blood , Female , Herpesvirus 6, Human/genetics , Humans , Interleukin-10/blood , Male , Middle Aged , Tumor Necrosis Factor-alpha/blood , Viral Load
13.
Bone Marrow Transplant ; 41(3): 279-85, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18037945

ABSTRACT

Human herpesvirus 6 (HHV-6) causes life-threatening encephalopathy in recipients of allogeneic SCT, but no consensus has been reached regarding appropriate preventive methods. This study evaluated a plasma HHV-6 viral load-guided preemptive approach against HHV-6-associated encephalopathy. Plasma real-time PCR assay was performed once a week. Among 29 patients, 19 developed positive plasma HHV-6 DNA. Median maximum plasma HHV-6 DNA was 4593.5 copies/ml plasma (range, 150.0-127 891.0 copies/ml plasma). In one of eight events with low-level HHV-6 DNA (defined as <1000 copies/ml plasma) and four of seven events with mid-level HHV-6 DNA (1000-9999.5 copies/ml plasma), HHV-6 loads in plasma subsequently continued increasing. Ganciclovir was administered against six of nine patients with high-level HHV-6 DNA (> or =10,000 copies/ml plasma). High-level HHV-6 DNA resolved similarly in both groups with or without ganciclovir therapy. Among the nine patients with high-level HHV-6 DNA two developed encephalopathy. As encephalopathy developed before the detection of high-level HHV-6 DNA in plasma, these two patients had not received preemptive ganciclovir therapy. In conclusion, our preemptive approach against HHV-6-associated encephalopathy cannot prevent all cases of HHV-6 encephalopathy in SCT recipients due to the dynamic kinetics of plasma HHV-6 viral load.


Subject(s)
Encephalitis, Viral/prevention & control , Hematopoietic Stem Cell Transplantation/adverse effects , Herpesvirus 6, Human/drug effects , Roseolovirus Infections/prevention & control , Viral Load , Adolescent , Adult , Antiviral Agents/therapeutic use , Chemoprevention , DNA, Viral/blood , Encephalitis, Viral/virology , Female , Ganciclovir/therapeutic use , Herpesvirus 6, Human/pathogenicity , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Prospective Studies , Transplantation, Homologous/adverse effects , Treatment Outcome
17.
Respir Med ; 99(1): 111-7, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15672859

ABSTRACT

Osteopontin (OPN) produced by alveolar macrophages functions as a fibrogenic cytokine in the development of bleomycin (BLM)-induced murine pulmonary fibrosis, and OPN mRNA is expressed on lung tissues from patients with idiopathic pulmonary fibrosis (IPF). The present study investigates plasma OPN levels in human interstitial pneumonia (IP) and their relationships with disease severity by analyzing the correlation between plasma OPN concentrations and pulmonary functions. The concentrations of OPN in plasma were measured in 17 patients with IP, in 9 with sarcoidosis and in 20 healthy controls using an antigen-capture enzyme-linked immunosorbent assay. The concentrations of OPN in plasma were significantly higher in IP patients than in those with sarcoidosis or in controls. Based on a Receiver Operating Characteristic curve analysis, cut-off points between 300 and 380 ng/ml discriminated between IP and control subjects with 100% sensitivity and 100% specificity. In such case, the sensitivity for sarcoidosis decreased (55.5-33.3%) in cut-offs with 100% specificity. Plasma OPN levels inversely and closely correlated with arterial oxygen tension (PaO2) in patients with IP. Immunohistochemically, OPN was localized predominantly in macrophages and airway epithelium. These findings suggest that plasma OPN levels were found to be associated with the presence of IP, and that OPN play an important role in the development of IP.


Subject(s)
Lung Diseases, Interstitial/blood , Sialoglycoproteins/blood , Adult , Aged , Biomarkers/blood , Carbon Monoxide/metabolism , Female , Humans , Immunoenzyme Techniques , Lung Diseases, Interstitial/metabolism , Lung Diseases, Interstitial/physiopathology , Macrophages, Alveolar/metabolism , Male , Middle Aged , Osteopontin , Oxygen/blood , Partial Pressure , Sarcoidosis, Pulmonary/blood , Sensitivity and Specificity , Sialoglycoproteins/metabolism , Sialoglycoproteins/physiology , Vital Capacity
18.
Eur Respir J ; 24(1): 57-65, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15293605

ABSTRACT

Heat shock protein (HSP) 47, a collagen-specific molecular chaperone, is involved in the processing and/or secretion of procollagen. The present study was undertaken to investigate whether treatment with the antifibrotic drug pirfenidone attenuates the bleomycin (BL)-induced overexpression of HSP47 in the lungs. Male ICR mice were intravenously injected with BL or saline (SA). Pirfenidone or control drug (CD) was administered 14 days after commencement of BL or SA, and continued throughout the course of the experiment. The mice were randomly divided into three experimental groups: 1) SA-treated with CD (SA group); 2) BL-treated with CD (BL group); and 3) BL-treated with pirfenidone (pirfenidone group). Lungs of the pirfenidone group showed a marked reduction of fibrotic lesions compared with the corresponding BL group. Immunohistochemical studies showed that BL treatment significantly increased the number of macrophages, myofibroblasts, HSP47-positive type II pneumocytes and HSP47-positive interstitial spindle-shaped cells. Treatment with pirfenidone significantly reduced the number of these cells compared with the corresponding BL group. Furthermore, treatment with pirfenidone significantly suppressed the BL-induced increase of the positive ratio of HSP47 and alpha-smooth muscle actin to interstitial spindle-shaped cells. The present study results showed that pirfenidone inhibited heat shock protein 47-positive cells and myofibroblasts, the principal cells responsible for the accumulation and deposition of extracellular matrix seen in pulmonary fibrosis.


Subject(s)
HSP70 Heat-Shock Proteins/drug effects , Hydroxyproline/metabolism , Pulmonary Fibrosis/drug therapy , Pulmonary Fibrosis/pathology , Pyridones/pharmacology , Analysis of Variance , Animals , Biopsy, Needle , Bleomycin , Disease Models, Animal , HSP70 Heat-Shock Proteins/metabolism , Hydroxyproline/analysis , Immunohistochemistry , Injections, Intravenous , Male , Mice , Mice, Inbred Strains , Probability , Random Allocation , Reference Values , Sensitivity and Specificity
19.
Eur Respir J ; 24(1): 143-9, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15293617

ABSTRACT

Coinfections of bacteria and influenza are a major cause of excessive mortality during influenza epidemics. However, the mechanism of the synergy between influenza virus and bacteria are poorly understood. In this study, mice were inoculated with influenza virus, followed 2 days later by inoculation with Streptococcus pneumoniae. The kinetics of viral titres, bacterial numbers and the immune response (cytokine and chemokine production) were also analysed. Short-term survival correlated with pathological changes in the lungs of infected mice. Influenza virus or S. pneumoniae infection alone induced moderate pneumonia; however, severe bronchopneumonia with massive haemorrhage in coinfected mice, which caused death of these mice approximately 2 days after inoculation with S. pneumoniae, was noted. Intrapulmonary levels of inflammatory cytokines/chemokines, type-1 T-helper cell cytokines and Toll-like receptors, and the related mitogen-activated protein kinase signalling molecules (phosphorylated extracellular signal-regulated kinase -1 and - 2, p38 and c-Jun N-terminal kinase), were increased in coinfected mice. These results suggest that immune mediators, including cytokines and chemokines, through Toll-like receptors/mitogen-activated protein kinase pathways, play important roles in the pathology of coinfection caused by influenza virus and Streptococcus pneumoniae.


Subject(s)
Biomarkers/analysis , Orthomyxoviridae/pathogenicity , Pneumonia, Bacterial/immunology , Pneumonia, Viral/immunology , Streptococcus pneumoniae/pathogenicity , Animals , Base Sequence , Blotting, Western , Cyclooxygenase 2 , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Membrane Glycoproteins/analysis , Membrane Glycoproteins/metabolism , Mice , Mice, Inbred Strains , Molecular Sequence Data , Pneumonia, Bacterial/mortality , Pneumonia, Viral/mortality , Polymerase Chain Reaction , Probability , Prostaglandin-Endoperoxide Synthases/analysis , Prostaglandin-Endoperoxide Synthases/metabolism , RNA, Messenger/biosynthesis , Receptors, Cell Surface/analysis , Receptors, Cell Surface/metabolism , Severity of Illness Index , Survival Rate , Toll-Like Receptors , Up-Regulation
20.
Respir Med ; 97(7): 844-50, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12854636

ABSTRACT

Diffuse panbronchiolitis (DPB) can now be cured with long-term erythromycin treatment. Our group conducted a prospective open trial of long-term treatment with a macrolide antibiotic, clarithromycin. We studied ten patients who were treated for 4 years with oral clarithromycin (200 mg once a day). Pulmonary function test, blood gas analysis, comprehensive improvement score, and bacterial culture of sputum were examined at 3, 6, 12 months, and at 2, 3, 4 years after the initiation of the therapy. Pulmonary function improved in most of the patients within 6 months: the forced expiratory volume in one second showed a maximal increase from a mean (SE) value of 1.74 (0.12) l at baseline to 2.31 (0.22) l at 6 months (P < 0.01) and the volume (l) of forced vital capacity also showed a maximal increase within 6 months. The partial pressure of arterial oxygen at rest significantly increased at 3-6 months. The comprehensive improvement score also reached maximum within 6 months in nine of the patients. The majority of patients have developed sputum culture in which bacteria were negative within 6 months after the therapy. All of the patients maintained a stable condition with continued therapy, and no side effects of clarithromycin were observed during the study. This prospective study demonstrated that 6-month treatment with clarithromycin might be necessary to improve the clinical conditions of patients with DPB and the drug could be safely used for a long term.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bronchiolitis/drug therapy , Clarithromycin/therapeutic use , Adult , Aged , Analysis of Variance , Bronchiolitis/microbiology , Bronchiolitis/physiopathology , Drug Administration Schedule , Female , Humans , Lung/physiopathology , Male , Middle Aged , Prospective Studies , Respiratory Function Tests , Sputum/microbiology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...